 CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Dec. 18, 2020 GLOBE NEWSWIRE -- Centogene N.V. Nasdaq: CNTG CENTOGENE or the Company, a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians and pharmaceutical companies, today announced the voting results of the Companys Extraordinary General Meeting. The shareholders of the Company voted in favor of all proposals, which included the appointments of Dr. Andrin Oswald as Managing Director and Dr. Jonathan Sheldon as Supervisory Director, the reappointment of Mr. Richard Stoffelen as Managing Director, and adjustments to the compensation of the Supervisory Board. 